X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vx-950 (89) 89
index medicus (84) 84
humans (77) 77
hepacivirus - drug effects (40) 40
hepatitis c (39) 39
antiviral agents - therapeutic use (37) 37
hepacivirus - genetics (36) 36
hepatitis c, chronic - drug therapy (35) 35
oligopeptides - therapeutic use (35) 35
hepatitis c virus (32) 32
antiviral agents - pharmacology (31) 31
drug therapy, combination (31) 31
ribavirin (31) 31
gastroenterology & hepatology (29) 29
pharmacology & pharmacy (29) 29
serine-protease (29) 29
telaprevir (29) 29
in-vitro (26) 26
protease inhibitor (26) 26
antiviral agents (24) 24
interferon-alpha - therapeutic use (24) 24
male (24) 24
oligopeptides - pharmacology (24) 24
hepatitis (22) 22
viral nonstructural proteins - antagonists & inhibitors (22) 22
protease inhibitors (21) 21
ribavirin - therapeutic use (21) 21
peginterferon alpha-2a (20) 20
hepacivirus - enzymology (19) 19
plus ribavirin (19) 19
polyethylene glycols - therapeutic use (19) 19
replication (19) 19
female (18) 18
infection (18) 18
middle aged (18) 18
genotype (17) 17
hepatitis c - drug therapy (17) 17
proteases (17) 17
adult (16) 16
interferon (16) 16
protease inhibitors - pharmacology (16) 16
recombinant proteins (16) 16
virology (16) 16
chemistry, medicinal (15) 15
drug resistance, viral (15) 15
drug therapy (15) 15
health aspects (15) 15
oligopeptides - adverse effects (15) 15
potent (15) 15
treatment outcome (15) 15
viral nonstructural proteins - genetics (15) 15
virus replication - drug effects (15) 15
antiviral agents - pharmacokinetics (14) 14
gastroenterology and hepatology (14) 14
hepatitis c, chronic - virology (14) 14
animals (13) 13
chronic hcv infection (13) 13
hcv (13) 13
resistance mutations (13) 13
rna (13) 13
antiviral agents - adverse effects (12) 12
genotype & phenotype (12) 12
hepatitis-c virus (12) 12
infectious diseases (12) 12
microbiology (12) 12
mutation (12) 12
care and treatment (11) 11
drug interactions (11) 11
drug resistance, viral - genetics (11) 11
oligopeptides - administration & dosage (11) 11
oligopeptides - pharmacokinetics (11) 11
peginterferon (11) 11
protease inhibitors - therapeutic use (11) 11
resistance (11) 11
therapy (11) 11
viruses (11) 11
abridged index medicus (10) 10
antiviral agents - administration & dosage (10) 10
biln-2061 (10) 10
clinical trials as topic (10) 10
combination (10) 10
combination therapy (10) 10
interferon-alpha (10) 10
ns3 protease (10) 10
proline - analogs & derivatives (10) 10
research (10) 10
viral load (10) 10
virus diseases (10) 10
biochemistry & molecular biology (9) 9
discovery (9) 9
inhibitor (9) 9
recombinant proteins - therapeutic use (9) 9
rna, viral - blood (9) 9
telaprevir vx-950 (9) 9
antiviral activity (8) 8
boceprevir (8) 8
cell line (8) 8
drug resistance (8) 8
genetic aspects (8) 8
hepacivirus - isolation & purification (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ISSN 0002-7863, 04/2008, Volume 130, Issue 14, pp. 4607 - 4607
Molecular modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3... 
IN-VITRO | VX-950 | VIRUS NS3 PROTEASE | C VIRUS | SERINE-PROTEASE | CHEMISTRY, MULTIDISCIPLINARY | DISCOVERY
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 2011, Volume 45, Issue 5, pp. 639 - 649
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 18, pp. 1839 - 1850
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 7/2013, Volume 57, Issue 2, pp. 221 - 229
Journal Article
Gastroenterology, ISSN 0016-5085, 2007, Volume 132, Issue 5, pp. 1767 - 1777
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 3, pp. 881 - 889.e1
Background & Aims We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in... 
Gastroenterology and Hepatology | Clinical Trial | Liver Disease | C209 | VX-950 | VX-951 | THERAPY | HEPATITIS-C VIRUS | COMBINATION | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Single-Blind Method | Hepatitis C, Chronic - metabolism | Interferon-alpha - pharmacology | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | RNA, Viral - genetics | Adult | Female | Drug Therapy, Combination | Polyethylene Glycols - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Recombinant Proteins - pharmacology | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Hepatitis C, Chronic - genetics | Oligopeptides - pharmacology | RNA, Viral - drug effects | Ribavirin - pharmacology | Evaluation | Complications and side effects | Care and treatment | RNA | Interferon | Genetic aspects | Hepatitis C | Hepatitis C virus | Consulting services | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 08/2019, Volume 10, Issue 1, pp. 1 - 11
Targeted protein degradation is a promising drug development paradigm. Here we leverage this strategy to develop a new class of small molecule antivirals that... 
TARGET | REPLICATION | ENZYME | VARIANTS | MULTIDISCIPLINARY SCIENCES | VX-950 | DEGRADATION | CELL-CULTURE | INHIBITOR | IDENTIFICATION | ADAPTER PROTEIN | Antiviral agents | Antiretroviral drugs | Proteinase | Viruses | Drug development | Proteins | Degradation | Disease resistance | Hepatitis | Protease | Antiviral activity | Proteasomes | New classes | Mutation | Hepatitis C virus | Hepatitis C | Index Medicus
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2008, Volume 52, Issue 12, pp. 4432 - 4441
Journal Article